25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

19 October 2019 - Event

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

27 May 2019 - BioVersys AG

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100

Dr. Glenn Dale, Chief Development Officer of BioVersys: “We are very pleased to receive QIDP designation from the FDA for…

BEAM News
Member News
Events

Latest news of BEAM Alliance

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

05 April 2018 - BEAM Alliance

EU-JAMRAI: BEAM Alliance becomes a new stakeholder

EU-JAMRAI [EU Joint Action on Antimicrobial Resistance (AMR) & Healthcare-Associated Infections (HCAI)] invited BEAM Alliance to take part as a new…

page 1/2

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

07 June 2019 - Polyphor Ltd

Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference

“Murepavadin is a precision antibiotic specifically targeting Pseudomonas aeruginosa, the main cause of chronic lung infection in cystic fibrosis. The…

06 June 2019 - Motif Bio plc

Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes

“We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with…

29 May 2019 - Polyphor Ltd

Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway

“This collaboration is a unique opportunity for the UZH and Polyphor to jointly develop antibiotics against priority 1 Gram-negative bacteria…

27 May 2019 - BioVersys AG

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100

Dr. Glenn Dale, Chief Development Officer of BioVersys: “We are very pleased to receive QIDP designation from the FDA for…

22 May 2019 - MaaT Pharma

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

“Our lead therapeutic, MaaT013, developed using our MMRB platform, has already yielded promising safety data in our ongoing Phase 2…

21 May 2019 - MEDINA

Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds

MEDINA is an internationally recognized leader in antimicrobial drug discovery and preclinical development and has contributed significantly to some of…

page 1/14

Events

13 November 2019

Matchmaking Symposium ‘Emerging Antimicrobials and Diagnostics in AMR 2019’

The event provides an excellent podium for emerging Antimicrobials and Diagnostics as well as an exciting program including orchestrated matchmakings,…

11 November 2019

BIO-Europe, 25th Annual International Partnering Conference

Celebrating 25 years of facilitating partnerships that drive life science dealmaking!

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

25 September 2019

Phage Futures Europe

Translating phage-based applications into clinically and commercially viable therapeutics

06 September 2019

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

This symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem…

03 September 2019

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…

09 July 2019

REVIVE webinar: Infection models for antimicrobial R&D: Intracellular models

In this webinar, Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain…

11 June 2019

REVIVE webinar: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

In this webinar, William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy, will introduce experimental…

05 June 2019

Advancing Data Technologies to corner Antimicrobial Resistance

Antimicrobial resistance (AMR) already now is the largest global threat to Health and Food Safety (source: WHO). Without the focused…

page 1/3